Q-omics provides the consensus-scored BMPR1B-DT profile across patient tissues and cancer cell-line models. BMPR1B-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, BMPR1B-DT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, BMPR1B-DT RNA expression shows 11,107 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, KIRC, and THYM as cancer lineages where BMPR1B-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMPR1B-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMPR1B-DT survival associations across molecular data types. BMPR1B-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMPR1B-DT RNA expression–survival associations across cancer types. High BMPR1B-DT expression shows unfavorable associations in READ, MESO, KIRC and UVM, but favorable associations in OV and UCEC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify READ as the clearest survival context for BMPR1B-DT RNA expression.
This table summarizes BMPR1B-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BMPR1B-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMPR1B-DT shows lower tumor expression in KIRC, KIRP, KICH, LUSC, LUAD and THCA. The KIRC box plot shows higher BMPR1B-DT RNA expression in normal versus tumor tissue (log2 FC = −2.217, t-test p < 0.001).
This table shows molecular features associated with BMPR1B-DT in patient tissues and cancer cell lines. In patient samples, BMPR1B-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
